Peer-influenced content. Sources you trust. No registration required. This is HCN.

The New England Journal of MedicineOnce-Weekly Semaglutide in Adolescents with Obesity

Among more than 200 adolescents 12 to 18 years of age over a 68-week period, nearly 75% of those in the treatment group experienced weight loss of > 5%, compared with only about 15% of those with placebo plus lifestyle intervention. GI adverse events were more common in the treatment group.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form